17. Multiple system atrophy Clinical trials / Disease details

Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05167721 (ClinicalTrials.gov)	December 15, 2021	30/11/2021	Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy	Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy	Multiple System Atrophy	Biological: Autologous Mesenchymal Stem Cells;Other: Placebo	Mayo Clinic	NULL	Recruiting	30 Years	70 Years	All	76	Phase 2	United States
2	NCT02315027 (ClinicalTrials.gov)	October 2012	31/10/2014	Mesenchymal Stem Cell Therapy in Multiple System Atrophy	Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History	MSA	Biological: Autologous Mesenchymal Stem Cells	Mayo Clinic	Food and Drug Administration (FDA);National Institute of Neurological Disorders and Stroke (NINDS)	Active, not recruiting	30 Years	80 Years	All	30	Phase 1/Phase 2	United States
3	NCT00911365 (ClinicalTrials.gov)	May 2008	26/5/2009	Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy	A Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy	Multiple System Atrophy	Biological: autologous mesenchymal stem cells;Biological: normal saline	Yonsei University	NULL	Completed	N/A	75 Years	Both	27	Phase 2	Korea, Republic of